Public Release:  New therapeutic target identified for Huntington's disease

PLOS

A new study published 26th November in the open access journal PLOS Biology, identifies a new target in the search for therapeutic interventions for Huntington's disease - a devastating late-onset neurodegenerative disorder.

The disease is genetic, affecting up to one person in 10,000, and from the age of about 35 leads to increasingly severe problems with movement, mental function, and behavior. Patients usually die within 20 years of onset, and there is to date no treatment that will modify the disease onset or progression.

Huntington's disease is caused by an unusual type of mutation in a gene that encodes the "huntingtin" protein. These mutations create long stretches of the amino acid glutamine within the protein chain, preventing huntingtin from folding properly and making it more 'sticky'. This causes huntingtin proteins to self-aggregate in both the nucleus and cytoplasm of cells, disrupting multiple aspects of cellular function and ultimately leading to the progressive death of nerve cells.

Nuclear huntingtin aggregates have been found to interfere with the transcription of many genes, and previous work has shown beneficial effects for Huntington's disease of inhibiting a family of enzymes that are normally thought to regulate transcription - the histone deacetylases, or HDACs. However, humans have eleven different HDAC enzymes, and it's been uncertain exactly which HDAC needs to be inhibited to see these benefits.

The new study from Michal Mielcarek, Gillian Bates and colleagues at King's College London has pinpointed just one of these enzymes as the target - HDAC4 - but with an intriguing twist; everything is happening in the cytoplasm, not the nucleus, and HDAC4's classic role in transcription has little to do with it.

The researchers noted that the HDAC4 protein naturally contains a region that, like mutant huntingtin, is rich in the amino acid glutamine. They show that HDAC4 can associate directly with huntingtin protein in a manner that depends on the length of the glutamine tracts, but that this association between HDAC4 and huntingtin occurs in the cytoplasm of nerve cells in the mouse brain, and - surprisingly - not in the nucleus, where HDAC4 is known to have its transcriptional role.

Bates and colleagues did their work in an aggressive disease mouse model of Huntington's disease - the gold standard model for this type of study. They find that halving the levels of HDAC4 in the cells of Huntington's disease mice can delay the aggregation of huntingtin in the cytoplasm, thereby identifying a new route to modulating the toxicity of mutant huntingtin protein. Crucially, reducing HDAC4 levels can also rescue the overall function of nerve cells and their synapses, with corresponding improvements seen in coordination of movement, neurological performance and lifespan of the mice. In agreement with the cytoplasmic association between HDAC4 and huntingtin, this all happens without any obvious improvement in the defective gene transcription in the nucleus.

There are currently no disease-modifying therapeutics available for Huntington's disease. It is still very early days and it is important to note that the medical applications of any therapy arising from this study have not been studied in a clinical setting and are far from clear. However, one broad-brush HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA) had previously been shown to improve movement defects in preclinical tests in this mouse model. The authors have shown in a related publication that, in addition to inhibiting HDAC enzyme function, SAHA decreases levels of the HDAC4 protein. Therefore it is hoped that the development of HDAC4-targeted compounds may be a promising strategy in improving the lot of Huntington's disease patients.

###

This work was performed by Gillian Bates' lab in King's College, London, in an international collaboration with scientists from the CHDI Foundation, Memorial Sloan Kettering Cancer Center (MSKCC, NY), Berlin, France and the Novartis Institute for BioMedical Research (Switzerland).

Please mention PLOS Biology as the source for this article and include the links below in your coverage to take readers to the online, open access articles

All works published in PLOS Biology are open access, which means that everything is immediately and freely available.

Use this URL in your coverage to provide readers access to the paper upon publication: http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1001717

Contact:

Dr Gillian Bates, PhD
King's College London
+44 20 7188 3722
gillian.bates@kcl.ac.uk

Citation: Mielcarek M, Landles C, Weiss A, Bradaia A, Seredenina T, et al. (2013) HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration. PLoS Biol 11(11): e1001717. doi:10.1371/journal.pbio.1001717

Funding: This work was supported by grants from the CHDI Foundation and Huntington's Disease Society of America (HDSA) to GB and from the DFG (SFB740 and SFB618), BMBF (NGFN-Plus, NeuroNet), HDSA, and the Helmholtz Association (MSBN, HelMA) to EEW. With the exception of the CHDI Foundation, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. CHDI Foundation is a not-for-profit biomedical research organization exclusively dedicated to discovering and developing therapeutics that slow the progression of Huntington's disease. The research at Neuroservice was conducted under a fee-for-service agreement for CHDI Foundation. Research conducted at King's College was performed in collaboration with and funded by the CHDI Foundation. In this case, the funder, through CHDI Management, fully participated in study design, data collection and analysis, the decision to publish, and preparation of the manuscript.

Competing Interests: Andreas Weiss and Herman van der Putten are employees of Novartis AG and potentially own shares in the company. Neuroservice conducted the research through a fee-for-service agreement for the CHDI Foundation. Larry Park and Vahri Beaumont are employed by CHDI Management Inc. to provide consulting services to CHDI Foundation. Amyaouch Bradaia, Kristian Wadel, and Chrystelle Touller are employees of Neuroservice. There are no patents, products in development, or marketed products to declare. We fully adhere to all the PLoS Biology policies on sharing data and materials, as detailed online in the guide for authors.

Disclaimer:

This press release refers to an upcoming article in PLOS Biology. The release is provided by journal staff, or by the article authors and/or their institutions. Any opinions expressed in this release or article are the personal views of the contributors, and do not necessarily represent the views or policies of PLOS. PLOS expressly disclaims any and all warranties and liability in connection with the information found in the releases and articles and your use of such information.

About PLOS Biology

PLOS Biology is an open-access, peer-reviewed journal published by PLOS, featuring research articles of exceptional significance, originality, and relevance in all areas of biology. For more information visit http://www.plosbiology.org, or follow @PLOSBiology on Twitter.

About PLOS:

The Public Library of Science (PLOS) is a nonprofit publisher and advocacy organization founded to accelerate progress in science and medicine by leading a transformation in research communication. PLOS engages in outreach activities that promote Open Access and innovations in the communication of research for scientists and the public. 2013 marks PLOS's tenth year as an Open Access publisher, reaching an international audience through immediate and free availability of research on the Internet. PLOS publishes a suite of seven journals: PLOS Biology, PLOS Medicine, PLOS Genetics, PLOS Computational Biology, PLOS Pathogens, and PLOS Neglected Tropical Diseases and PLOS ONE, which publishes research from more than 50 diverse scientific fields and is the largest journal in the world.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.